Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1998-09-02
2001-02-06
Low, Christopher S. F. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S008100, C514S011400, C514S012200, C514S017400, C514S018700, C530S300000, C530S317000, C530S324000, C530S327000, C530S329000, C530S331000, C530S380000, C530S382000, C530S395000
Reexamination Certificate
active
06184206
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is related to the field of dissociating ligands from the receptors to which they bind. In particular, the present invention relates to dissociating ligands from integrins and thus treating diseases or conditions associated with binding of the ligands.
2. Background Art
Anti-platelet compounds are useful in treating many cardiovascular diseases including myocardial infarction, restenosis, unstable angina and possibly even atherosclerosis. One target for anti-platelet drugs is the platelet surface receptor called GPIIb-IIa. GPIIb-IIIa is an &agr;&bgr; heterodimer present on the platelet surface and is the platelet fibrinogen receptor. At wounds or sites of vascular injury, GPIIb-IIIa mediates platelet adhesion and platelet aggregation. The formation of these platelet thrombi halt blood loss. Unfortunately, platelets can also adhere aberrantly to blood vessel walls, particularly at sites of atherosclerotic plaques. These platelet-rich thrombi can cause unstable angina and when activated, can lead to myocardial infarct.
GPIIb-IIa is a member of the integrin protein family of cell adhesion receptors. GPIIb-IIIa is one of the integrins that can bind to the arg-gly-asp (RGD) peptide motif. This peptide motif is found within a number of adhesive proteins and also in several of the ligands for IIb-IIIa. The primary physiologic ligand for GPIIb-IIIa is fibrinogen, a soluble plasma borne protein that contains two RGD motifs.
There is now great interest in developing small molecule antagonists of IIb-IIIa. Many candidate antagonists of IIb-IIIa have been developed. Most of these are structural mimics of RGD. Current understanding of IIb-IIIa indicates that it contains a single ligand binding pocket which can bind to both RGD and to the gamma chain sequence of fibrinogen. Hence, it is believed that antagonists of IIb-IIIa which bind at this single ligand binding site will be efficacious in preventing the formation of platelet aggregates because they will block the association of fibrinogen with IIb-IIIa.
The present invention provides evidence that IIb-IIIa contains at least two ligand binding pockets and that these two sites are interacting (FIG.
2
). The present invention also provides evidence that ligands which bind at Ligand Binding Site I can enact the dissociation of ligand that is already pre-bound at Site II. Because of their unique ability to induce the dissociation of fibrinogen from IIb-IIIa, these antagonists are called Integrin-Ligand Dissociators. Furthermore, the present invention demonstrates that Integrin-Ligand Dissociators are able to enact the dissolution of pre-formed platelet aggregates. These findings indicate a novel approach toward anti-platelet therapy that is a strong departure from the current prophylactic strategy of applying antagonist prior to formation of vascular occlusions. Rather, the present invention demonstrates that the Integrin-Ligand Dissociators of this invention can be applied to reverse platelet aggregates that have already formed.
SUMMARY OF THE INVENTION
The present invention provides a method of disaggregating an existing platelet thrombus in a blood vessel in a subject, comprising administering to the subject a compound which dissociates fibrinogen bound to a first site on platelet glycoprotein IIb-IIIa, by binding a second interacting site on platelet glycoprotein IIb-IIIa, thereby disaggregating the platelet thrombus.
Further provided is a method of screening a compound for the ability to dissociate a ligand from its integrin receptor by binding an interacting second site, comprising contacting the compound with an existing ligand:integrin receptor complex and determining if the complex dissociates.
The present invention additionally provides a method of dissociating a ligand bound to a first site on an integrin receptor, comprising contacting a ligand:integrin receptor complex with a molecule capable of binding a second interacting site on the integrin receptor, thereby dissociating the ligand bound to a first site on the integrin receptor.
Various other objectives and advantages of the present invention will become apparent from the following detailed description.
REFERENCES:
patent: 4666884 (1987-05-01), Hawiger et al.
patent: 5470738 (1995-11-01), Frelinger, III et al.
patent: 5654267 (1997-08-01), Vuori et al.
patent: 5773412 (1998-06-01), Cheng et al.
patent: 5792745 (1998-08-01), Cheng et al.
Mousa et al. “Antiplatelet and Antithrombotic Efficacy of DMP 728, a Novel Platelet GPIIb/IIIa Receptor Antagonist”Circulation89(1):3-12, Jan. 1994.
Phillips et al. “GPIIb-IIIa: The Responsive Integrin”Cell65:359-362, May 3, 1991.
Cook et al. “Nonpeptide Glycoprotein IIb/IIIa Inhibitors. 15. Antithrombotic Efficacy of L-738, 167, a Long-Acting GPIIb/IIIa Antagonist, Correlates with Inhibition of Adenosine Diphosphate-Induced Platelet Aggregation but not with Bleeding Time Prolongation”J. Pharm. and Experimental Therapeutics, 281 (2) :677-689, 1997.
Kaida et al. “Antiplatelet Effect of FK633, a Platelet Glycoprotein IIb/IIIa Antagonist, on Thrombus Formation and Vascular Patency after Thrombolysis in the Injured Hamster Cartoid Artery”Thrombosis and Haemostasis77(3):562-567, 1997.
Mousa et al. “Prevention of Carotid Artery Thrombosis by Oral Platelet GPIIb/IIIa Antagonist in Dogs”Stroke28(4):830-836, Apr. 1997.
Frishman et al. “Novel Antiplatelet Therapies for Treatment of Patients with Ischemic Heart Disease:Inhibitors of the Platelet Glycoprotein IIb/IIIa Integrin Receptor”Am. Heart J. 130:877-892, Oct., 1995.
Smith et al. “Protein Loop Grafting to Construct a Variant of Tissue-type Plasminogen Activator that Binds Platelet Integrin&agr;IIb&bgr;3”J. Biol. Chem.270(51):30486-30490, Dec. 22, 1995.
Coller et al. “New Antiplatelet Agents: Platelet GPIIb/IIIa Antagonists”Thrombosis and Haemostasis74(1):302-308, 1995.
Smith et al. “Building Synthetic Antibodies as Adhesive Ligands for Integrins”J. Biol. Chem. 269(52):32788-32795, 1994.
Smith et al. “A Mechanism for Divalent Cation Regulation of &bgr;3-Integrins”J. Biol. Chem. 269(2):960-967, Jan. 14, 1994.
Smith et al. “Building Synthetic Antibodies as Adhesive Ligand for Integrins”J. Biol. Chem. 269(52):32788-32795, Dec., 1994.
Nicholson et al. “SC-49992-A Potent and Specific Inhibitor of Platelet Aggregation”Thrombosis Research74(5):523-535, 1994.
Barbas et al. “High-Affinity Self-Reactive Human Antibodies by Design and Selection: Targeting the Integrin Ligand Binding Site”Proc. Natl. Acad. Sci. USA90:1003-1007, Nov. 1993.
Zablocki et al. “Potent in vitro and in vivo Inhibitors of Platelet Aggregation Based upon the Arg-Gly-Asp-Phe Sequence of Fibrinogen. A Proposal on the Nature of the Binding Interaction between the Arg-Guanidine of RGDX Mimetics and the Platelet GP IIb-IIIa Receptor”J. Med. Chem. 36:1811-1819, 1993.
Calvete et al. “Localization of the Cross-Linking sites of RGD and KQAGDV Peptides to the Isolated Fibrinogen Receptor, the Human Platelet Integrin Glicoprotein IIb/IIIa Influence of Peptide Length”Eur. J. Biochem. 206:759-765, 1992.
Cheresh, David and Spiro, Robert “Biosynthetic and Functional Properties of an Arg-Gly-Asp-Directed Receptor Involved in Human Melanoma Cell Attachment to Vitronectin, Fibrinogen, and von Willebrand Factor”J. Biol. Chem. 262(36):17703-17711, Dec. 1987.
Coller, Barry S. “A New Murine Monoclonal Antibody Reports an Activation-Dependent Change in the Conformation and/or Microenvironment of the Platelet Glycoprotein IIb/IIIa Complex”J. Clin. Invest. 76:101-108, Jul. 1985.
Frishman et al., Am. Heart. J. vol. 130, pp. 877-892, Oct. 1995.
Hu Dana D.
Smith Jeffrey W.
Low Christopher S. F.
Mohamed Abdel A.
Needle & Rosenberg P.C.
The Burnham Institute
LandOfFree
Integrin ligand dissociators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Integrin ligand dissociators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Integrin ligand dissociators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2612444